Publications by authors named "T Geldart"
Introduction: SCLC is characterized by aggressiveness and limited treatment options, especially in extensive-stage SCLC (ES-SCLC). Immunotherapy added to the platinum-etoposide combination has recently become standard in this setting. This retrospective study aims to evaluate the real-world effectiveness of chemo-immunotherapy in patients with ES-SCLC, focusing on subpopulations excluded from clinical trials.
View Article and Find Full Text PDFArticle Synopsis
- The study focused on the long-term effects of afatinib in patients with EGFR mutant non-small cell lung cancer (NSCLC) who also had other health issues, and assessed the usefulness of monitoring circulating tumor DNA (ctDNA).
- Conducted in the UK, the TIMELY trial involved patients receiving afatinib daily until their disease progressed or they experienced significant side effects, with blood samples analyzed every 12 weeks.
- Results showed that while the median progression-free survival was 7.9 months, some patients experienced long-term benefits, and ctDNA testing improved the detection of EGFR mutations and was linked to better outcomes.
Purpose: Current guidelines for the management of metastatic non-small cell lung cancer (NSCLC) without driver mutations recommend checkpoint immunotherapy with PD-1/PD-L1 inhibitors, either alone or in combination with chemotherapy. This approach fails to account for individual patient variability and host immune factors and often results in less-than-ideal outcomes. To address the limitations of the current guidelines, we developed and subsequently blindly validated a machine learning algorithm using pretreatment plasma proteomic profiles for personalized treatment decisions.
View Article and Find Full Text PDFArticle Synopsis
- The ASTRIS study analyzed the effects of osimertinib, a treatment for advanced EGFR T790M non-small-cell lung cancer (NSCLC), in 3,014 patients who had previously received EGFR-TKI therapy.
- The main outcomes were overall survival (OS), with a median of 22.8 months, and progression-free survival (PFS) at 11.1 months, indicating positive treatment effectiveness.
- Results also showed better OS in patients with good performance status and those without brain metastases, with no new safety concerns reported throughout the study.
Purpose: Survival in stage I seminoma is almost 100%. Computed tomography (CT) surveillance is an international standard of care, avoiding adjuvant therapy. In this young population, minimizing irradiation is vital.
View Article and Find Full Text PDF